▎药明康德内容团队编辑
图片来源：CDE官网
参考资料（可上下滑动查看）
[1]中国国家药监局药品审评中心（CDE）官网. Retrieved Mar 18, 2023, from https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d
[2] Novaliq announces FDA acceptance of the new drug application for CyclaSol® for the treatment of dry eye disease. Retrieved October 24, 2022 from https://www.novaliq.com/press-releases/2022/10/24/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/
[3]恒瑞医药关于引进德国Novaliq公司产品的公告.Retrieved Nov 8,2019,from http://www.cninfo.com.cn/new/disclosure/detail?plate=sse&orgId=gssh0600276&stockCode=600276&announcementId=1207073250&announcementTime=2019-11-08
[4] Novaliq Announces Positive Topline Results for Second Phase 3 Trial (Essence-2) of CyclASol® in Dry Eye Disease. Retrieved December 21, 2021, from https://www.novaliq.com/press-releases/2021/12/21/novaliq-announces-positive-topline-results-for-second-phase-3-trial-essence-2-of-cyclasol-in-dry-eye-disease/
[5]恒瑞医药创新药SHR8028滴眼液获批临床.Retrieved Dec 24，2020,from https://mp.weixin.qq.com/s/ejdYhaTvg1mQ40Wts1HZzA
本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。
免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。